Milla Koistinaho is a founder and Non-Executive Director of Aranda Pharma Ltd. Milla has over 15 years of experience in commercializing biomedical inventions and developing business models especially in the therapeutic areas of CNS diseases and oncology. She has been a member of founding team in three start-up companies in Finland. For 9 years Milla has served as a founding CEO at Medeia Therapeutics Ltd and been responsible for IPR generation, leading research programs and partnerships, executing financing rounds and leading business development actions. Milla has also been CSO and CEO in Cerebricon Ltd serving clients in pharmaceutical development. She is well networked internationally and she has also worked as a postdoctoral researcher in biopharmaceutical projects at Eli Lilly and Company in the USA. Milla holds Adjunct Professorship in neurobiology at University of Eastern Finland. She has a PhD degree from the same university. Milla gained her PhD thesis in collaboration with Stanford University and Scios Inc., California, USA. Currently Milla is the Director of Life Sciences at the Helsinki Innovation Services Ltd, Finland.  

 Neurobiology